Key result
PEGylated liposomal doxorubicin rechallenge shows no pancreatitis recurrence in a patient with prior doxorubicin-induced pancreatitis.
Why the study?
Drug-induced pancreatitis is rare and difficult to establish causality, with conventional doxorubicin carrying a high recurrence risk upon rechallenge in patients needing continued breast cancer chemotherapy.
Does substituting conventional doxorubicin with PEGylated liposomal doxorubicin prevent recurrence of pancreatitis in patients with prior doxorubicin-induced pancreatitis?
Case Report (n=1)
Does substituting conventional doxorubicin with PEGylated liposomal doxorubicin prevent recurrence of pancreatitis in patients with prior doxorubicin-induced pancreatitis?
Substituting conventional doxorubicin with PEGylated liposomal doxorubicin may be a safe strategy for continued chemotherapy in patients who develop doxorubicin-induced pancreatitis.
Answers are grounded in this paper and cite their sources.
Doxorubicin-induced pancreatitis warrants vigilance during breast cancer chemotherapy; leaves open prospective evaluation of rechallenge safety and causality.
Drug induced pancreatitis is rare and establishing the exact causal relationship is challenging. Here, we discuss the management of a 60 year-old female patient with stage 3a breast cancer who developed doxorubicin induced pancreatitis 3 days after her first treatment with cyclophosphamide and doxorubicin chemotherapy. This patient had locally advanced cancer and there remained a significant risk of metastatic disease in the absence of chemotherapy. Therefore, she opted for rechallenge despite the risk of recurrent pancreatitis. She commenced cyclophosphamide and PEGylated-liposomal doxorubicin at 30mg/m2, instead of conventional doxorubicin and tolerated this well, without recurrence of pancreatitis. Doxorubicin is becoming increasingly associated with pancreatitis, with high incidence of recurrence upon rechallenge. PEGylated liposomal doxorubicin has not been shown to cause pancreatitis and there is evidence supporting its use for treating breast cancer. A potential strategy for continued treatment following doxorubicin-induced pancreatitis, may be to substitute conventional doxorubicin with PEGylated liposomal doxorubicin.
No takes yet. Share an insight, caveat, or question.
Ardolino et al. (2020) conducted a case report in Stage 3a breast cancer with doxorubicin-induced pancreatitis (n=1). PEGylated-liposomal doxorubicin vs. Conventional doxorubicin was evaluated on Recurrence of pancreatitis. Rechallenge with PEGylated liposomal doxorubicin at /m2 was well tolerated without recurrence of pancreatitis in a patient who previously developed doxorubicin-induced pancreatitis.
Synapse has enriched 10 related papers. Consider them for comparative context: